Stafylidis, C.; Vlachopoulou, D.; Kontandreopoulou, C.-N.; Diamantopoulos, P.Τ. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia. J. Clin. Med.2024, 13, 1082.
Stafylidis, C.; Vlachopoulou, D.; Kontandreopoulou, C.-N.; Diamantopoulos, P.Τ. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia. J. Clin. Med. 2024, 13, 1082.
Stafylidis, C.; Vlachopoulou, D.; Kontandreopoulou, C.-N.; Diamantopoulos, P.Τ. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia. J. Clin. Med.2024, 13, 1082.
Stafylidis, C.; Vlachopoulou, D.; Kontandreopoulou, C.-N.; Diamantopoulos, P.Τ. Unmet Horizons: Assessing the Challenges in the Treatment of TP53-Mutated Acute Myeloid Leukemia. J. Clin. Med. 2024, 13, 1082.
Abstract
Acute myeloid leukemia (AML) remains a challenging hematologic malignancy. The presence of TP53 mutations in AML poses a therapeutic challenge, considering that standard treatments face significant setbacks in achieving meaningful responses. There is a pressing need for the development of innovative treatment modalities to overcome resistance to conventional treatments attributable to the unique biology of TP53-mutated (TP53mut) AML. This review underscores the role of TP53 mutations in AML, examines the current landscape of treatment options, and highlights novel therapeutic approaches, including targeted therapies, combination regimens, and emerging immunotherapies as well as agents being explored in preclinical studies, for their potential to address the unique hurdles posed by TP53mut AML.
Keywords
acute myeloid leukemia; TP53 mutations; TP53-mutated acute myeloid leukemia; novel targeted AML therapies; AML immunotherapies
Subject
Medicine and Pharmacology, Hematology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.